Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection
Khalida Shamim(National Institutes of Health), Wenwei Huang(National Institutes of Health), Catherine Z. Chen(National Institutes of Health), Richard T. Eastman(National Institutes of Health), Hongjun Song(Shanghai Sixth People's Hospital), Ruili Huang(National Institutes of Health), Emily M. Lee(Florida State University), Wei Zheng(Liaoning Cancer Hospital & Institute), Hengli Tang(Florida State University), Zina Itkin(National Institutes of Health), Carleen Klumpp‐Thomas(National Institutes of Health), Sam Michael(National Institutes of Health), Anton Simeonov(National Institutes of Health), Min Shen(Kaili University), Lu Chen(Chengdu University of Traditional Chinese Medicine), Miao Xu(National Institutes of Health), Xin Hu(Discovery Institute), Xiao Lü(National Institutes of Health), Xin Xu(National Institutes of Health), Pranav Shah(Uka Tarsadia University), Hui Guo, Donald C. Lo(Center for Translational Molecular Medicine), Paul Shinn(National Institutes of Health), Guo‐li Ming(University of Pennsylvania)
Cited by 25
Related Papers
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
|Nature Medicine|2016|570
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|391
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Erratum: Unexplored therapeutic opportunities in the human genome
|Nature Reviews Drug Discovery|2018|327